Reckitt's New CEO Wants Immediate Changes As OTC Sales Slump In Q3
Executive Summary
RB's new CEO Laxman Narasimhan is unforgiving about how the company has been run over the past few years and believes things need to change after another disappointing quarter.
You may also be interested in...
RB To Split OTC And Infant Nutrition As CEO Hits Reset Button
Reckitt Benckiser's new CEO Laxman Narasimhan has unveiled a turnaround plan which will see the company's OTC drugs and dietary supplements housed in a separate business to its infant nutrition products. RB is investing £2bn to get back on track after a couple of difficult years.
Reckitt Names New CEO To Ignite Growth And Lead Digital Transformation
Reckitt Benckiser has poached PepsiCo's global chief commercial officer, Laxman Narasimhan, to replace Rakesh Kapoor as the UK-based firm's CEO. Setting his stall out early, Narasimhan has made clear that RB's "capabilities and culture" need to change to make the company fit for the new digital world.
Infant Formula Production Stalls On Reckitt Benckiser's Latest Stumble
A "technical problem" interrupted infant formula production at firm's Netherlands plant during third quarter, causing a 8% dive in its revenues from Enfamil and other brand formulas. The problem has been corrected but revenues will be slowed during the current quarter and likely into early 2019. But analysts say the imapct could be deeper impact because it's the fourth problems since 2011 RB should have avoided.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: